PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Susana Banerjee, MBBS, MA, FRCP, PhD / William J. Gradishar, MD, FASCO, FACP / Maha Hussain, MD, FACP, FASCO
Go online to PeerView.com/VHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of improved understanding of the genetic mechanisms underlying solid tumors, PARP inhibitors are now validated treatments for patients with ovarian, prostate, breast, and pancreatic cancers. Targeting DNA damage response (DDR) mutations, which have an important role in tumorigenesis, PARP inhibitors are now being studied in other cancers, as well as in combination with immunotherapies and other agents. Approvals of PARP inhibitors have, in some cases, brought with them approvals of companion diagnostics or complementary diagnostic tests. Join a panel of oncology experts for a PeerView MasterClass providing in-depth education on PARP inhibitors, including the rationale for their use, the latest efficacy and safety data in a variety of tumor types, and investigational uses of these agents. Didactic presentations will be supplemented with a practicum session featuring guidance and clinical perspectives on diagnostic testing, dosing considerations, managing AEs associated with PARP inhibitors, and selecting patients for clinical trial enrollment. Upon completion of this accredited CE activity, participants should be better able to: Discuss the rationale for use and the expanding role of PARP inhibitors in the treatment of different cancers, including malignancies of the ovaries, prostate, breast, and pancreas, Describe the efficacy and safety profiles of PARP inhibitors and the role of diagnostic testing in guiding patient selection across a range of cancers, Implement appropriate strategies for integrating PARP inhibitors, either through approved indications or clinical trial enrollment, into treatment plans for patients with cancer, Formulate strategies to prevent and/or manage PARP inhibitor–associated AEs.